

Nr Book	Abstract Title	Presenter	City	Country	OUTCOME	Topic
1	IMMUNOTHERAPY COMES OF AGE TO TREAT LYMPHOMAS	Levy, Ronald	Stanford, CA	USA	oral	
2	GENETIC SIGNATURES AND TARGETABLE PATHWAYS IN LYMPHOID MALIGNANCIES	Shipp, Margaret	Boston, MA	USA	oral	
3	GENOMES IN TRANSIT: WHAT MULTI-OMICS CAN TELL US ON LYMPHOMAS	Siebert, Reiner	Ulm	Germany	oral	
4	INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMTOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA	Morschhauser, Franck	Lille	France	oral	
5	CRISPR-Cas9 genetic screens uncover a B cell receptor-MYD88 superpathway in diffuse large B cell lymphoma	Young, Ryan	Bethesda, Maryland	USA	oral	
6	BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)	Cramer, Paula	Cologne	Germany	oral	
7	GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS	Schuster, Stephen	Philadelphia	USA	oral	
8	Axicabtagene ciloleuce (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL): primary results of the pivotal trial ZUMA-1	Neelapu, Sattva	Houston	USA	oral	
9	WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM MALIGNANT MELANOMA?	Eggermont, Alexander	Villejuif	France	oral	
10	WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER?	Stahel, Rolf	Zurich	Switzerland	oral	
11	Outcome of curative radiotherapy for localised follicular lymphoma in the era of ¹⁸ F-FDG PET-CT staging: an international collaborative study on behalf of ILROG	Brady, Jessica	London	UK	oral	
12	CVP or R-CVP given after involved-field radiotherapy improves progression free survival in stage I-II follicular lymphoma: Results of an International Randomized Trial	MacManus, Michael	Melbourne	Australia	oral	
13	Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, R-FCM) in previously untreated follicular lymphoma: a randomised trial of GLSG and OSHO	Hoster, Eva	München	Germany	oral	
14	Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT Lymphoma Working Party Lym1 trial	Pettengell, Ruth	London	UK	oral	
15	Long term results of the FOLLO5 randomized study comparing R-CVP with R-CHOP and R-FM as first line therapy in patients with advanced stage Follicular Lymphoma. A FIL study.	Luminari, Stefano	Reggio Emilia	Italy	oral	
16	Cause of death in follicular lymphoma in the rituximab era: a pooled analysis of French and US cohorts.	Sarkozy, Clémentine	Pierre Bénite	France	oral	
17	Prognostic value of baseline total metabolic tumor volume (TMTV) for patients with early stage Hodgkin lymphoma enrolled in the standard arm of the H10 (EORTC/LYSA/FIL) trial.	COTTEREAU, Anne-Ségolène	PARIS	France	oral	
18	Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE	Moskowitz, Alison	New York	USA	oral	
19	Can baseline PET-CT features predict outcomes in advanced Hodgkin Lymphoma? A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033).	Pike, Lucy	London	UK	oral	
20	CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL)	Rigacci, Luigi	Florence	Italy	oral	
21	Prognostic value of PET-CT after first-line immunochemotherapy for follicular lymphoma in the Phase III GALLIUM study	Trotman, Judith	Sydney	Australia	oral	
22	FDG-PET as a biomarker of response in DLBCL: The HOVON 84 study experience	Burggraaff, Coreline	Amsterdam	Netherlands	oral	
23	Non-mediastinal cases of grey zone lymphoma: a pathological and clinical series of 17 cases from the LYSA.	Sarkozy, Clémentine	Pierre Bénite	France	oral	
24	FOXP1 expression is inversely correlated with EZH2 mutation status and predicts poor failure-free survival in follicular lymphoma treated with rituximab and chemotherapy	Mottok, Anja	Vancouver	Canada	oral	
25	Elevated expression of LAG3 is associated with poor outcome in patients with DLBCL treated with R-CHOP.	Keane, Colm	Woolloongabba	Australia	oral	
26	Cell of origin combined with CNS International Prognostic Index improves identification of DLBCL patients with high CNS relapse risk after initial immunochemotherapy	Klanova, Magdalena	Basel	Switzerland	oral	
27	NKp46 expression is a diagnostic and prognostic biomarker in primary gastrointestinal T-cell lymphoproliferations. A CELAC network study.	Cheminant, Morgane	Paris	France	oral	
28	Adult Patients with CAEBV-like Features: A Distinct Subtype of Epstein-Barr Virus positive T/NK-cell Lymphoproliferative Disorder	Kawamoto, Keisuke	Kurume	Japan	oral	
29	PHARMACOLOGICAL ACTIVITY OF CB-103 IN HAEMATOLOGICAL MALIGNANCIES – AN ORAL pan-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION	Weber, Dirk	Basel	Switzerland	oral	
30	Anti-tumor activity of daratumumab, a novel human CD38 monoclonal antibody, in vitro and in vivo models of B-cell Non-Hodgkin Lymphoma	Pérez-Galán, Patricia	Barcelona	Spain	oral	
31	A new BCL-2 inhibitor (S55746/BCL201) as monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: Preliminary results of the first-in-human study	Le Gouill, Steven	Nantes	France	oral	
32	Phase I of IPH4102, anti-KIR3DL2 mAb, in relapsed/refractory Cutaneous T-Cell Lymphomas (CTCL): dose-escalation safety, biomarker and clinical activity results.	Bagot, Martine	Paris	France	oral	

33	A phase 1 study of the anti-CD37 antibody-drug conjugate AGS67E in advanced lymphoid malignancies. Interim results.	Sawas, Ahmed	New York	USA	oral	
34	First Clinical Results of ADCT-402, a Novel Pyrrolbenzodiazepine-Based Antibody Drug Conjugate (ADC), in Relapsed/Refractory B-cell Lineage NHL	Kahl, Brad	St. Louis	USA	oral	
35	Final results of CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma	Martin, Peter	New York	USA	oral	
36	L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) – a single-arm phase II study	Salles, Gilles	Pierre Bénite	France	oral	
37	A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Follicular B-Cell Lymphoma	Morschhauser, Franck	Lille	France	oral	
38	Phase Ib study of CC-122 in combination with obinutuzumab (GA101): relapsed or refractory (R/R) patients with B-cell non-Hodgkin lymphoma (NHL)	Michot, Jean	Villejuif	France	oral	
39	Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma	Batlevi, Connie	New York	USA	oral	
40	Updated Results of a Multicenter Phase I/Ib Study of TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory MCL or CLL	Davids, Matthew	Boston	USA	oral	
41	GB Virus-C (GBV-C) Infection and Risk of Lymphoma: a Case-Control Study from North America	Fama, Angelo	Rochester	USA	oral	
42	Drug Perturbation Based Stratification of Lymphoproliferative Disorders	Dietrich, Sascha	Heidelberg	Germany	oral	
43	ETS1 positively regulates FAIM3 in activated B cell-like (ABC) diffuse large B cell lymphoma (DLBCL)	Priebe, Valdemar	Bellinzona	Switzerland	oral	
44	NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS	Pozzo, Federico	Aviano	Italy	oral	
45	Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma	Sakata-Yanagimoto, Mamiko	Ibaraki	Japan	oral	
46	Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma	Boddicker, Rebecca	Rochester, MN	USA	oral	
47	Molecular classification of primary mediastinal large B cell lymphoma using formalin-fixed, paraffin-embedded tissue specimens – an LLMP project	Mottok, Anja	Vancouver	Canada	oral	
48	Metabolic Heterogeneity on Baseline 18-FDG PET-CT Scan Predicts Outcome in Primary Mediastinal B-Cell Lymphoma.	Ceriani, Luca	Bellinzona	Switzerland	oral	
49	Outcomes of Adults, Adolescents, and Children with Primary Mediastinal B-Cell Lymphoma Treated with Dose-Adjusted EPOCH-R Therapy: A Multicenter Retrospective Analysis	Roth, Lisa	New York	USA	oral	
50	Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial	Zinzani, Pier Luigi	Bologna	Italy	oral	
51	Restore & Target: A conceptually novel treatment approach to classical Hodgkin's lymphoma	Schmitt, Clemens	Berlin	Germany	oral	
52	GENOTYPING OF CLASSICAL HODGKIN LYMPHOMA ON THE LIQUID BIOPSY	Bruscaggin, Alessio	Bellinzona	Switzerland	oral	
53	eBEACOPP with or without Rituximab in Interim-PET-Positive Advanced-Stage Hodgkin Lymphoma: Updated Results of the International, Randomized Phase 3 GHSG HD18 Trial	Borchmann, Peter	Cologne	Germany	oral	
54	Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: longer follow up confirms efficacy of de-escalation after a negative interim PET scan (CRUK/07/033).	Trotman, Judith	Concord	Australia	oral	
55	Blockade of the PD-1 checkpoint with anti-PD-L1 antibody avelumab is sufficient for clinical activity in relapsed/refractory classical Hodgkin Lymphoma (cHL)	Chen, Robert	Duarte	USA	oral	
56	Combined risk of second malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors	Aleman, Berthe	Amsterdam	Netherlands	oral	
57	Clinical outcomes and molecular characterization from a phase II study of copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma	Lenz, Georg	Münster	Germany	oral	
58	DYNAMO: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma	Zinzani, Pier Luigi	Bologna	Italy	oral	
59	Bruton's tyrosine kinase (BTK) inhibitor BGB-3111 demonstrates high very good partial response (VGPR) rate in patients with Waldenström macroglobulinemia (WM)	Trotman, Judith	Concord	Australia	oral	
60	Ibrutinib in Relapse or Refractory Primary CNS and Vitreo-Retinal Lymphoma. Results of the primary end-point of the /LOC phase II study from the LYSA and the French LOC network.	Soussain, Carole	Saint-Cloud	France	oral	
61	TAK-659, an investigational reversible dual SYK/FLT-3 inhibitor, in patients with lymphoma: Updated results from dose-escalation and expansion cohorts of a phase 1 study	Kaplan, Jason	Chicago	USA	oral	
62	The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B-Cell Malignancies	Hamlin, Paul	Basking Ridge, NJ	USA	oral	
63	Gene expression profiling using a RTMLPA assay allows for an accurate classification of peripheral T-cell lymphoma and highlights novel subgroups within PTCLs-NOS	Ruminy, Philippe	Rouen	France	oral	
64	CHOP versus GEM-P in the first-line treatment of T-cell lymphoma: initial results of the UK NRCI phase II randomised CHEMO-T trial	Gleeson, Mary	Sutton	UK	oral	
65	Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma: A propensity score matching analysis of patients from LYSA centers	Fossard, Gaëlle	Pierre Bénite	France	oral	
66	Brentuximab Vedotin vs Physician's Choice in CTCL Patients from the Phase 3 ALCANZA study: Analysis of Outcomes by CD30 Expression	Kim, Youn	Stanford	USA	oral	

67	Improved survival outcomes for patients with extra-nodal NK/T lymphoma; data from 140 patients prospectively registered in the International T-Cell Project.	Fox, Christopher	Nottingham	UK	oral	
68	GAD-M regimen for newly diagnosed extranodal NK/T cell lymphoma: analysis of efficacy and safety from Phase II Study (NCT 01991158)	Li, Z.	Guang Zhou	China	oral	
69	Results of a phase II study of brentuximab vedotin in the first line treatment of Hodgkin lymphoma patients considered unsuitable for standard chemotherapy (BREVITY)	Gibb, Adam	Manchester	UK	oral	
70	Brentuximab Vedotin Consolidation to Reduce Radiation Use in Patients with Limited Stage Non-bulky Hodgkin Lymphoma: An Update from a Phase 2 Clinical Trial	Park, Steven	Charlotte	USA	oral	
71	Results of a multicentre UK-wide study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the pre-transplant naive setting	Eyre, Toby	Oxford	UK	oral	
72	Brentuximab Vedotin for relapsed Hodgkin lymphoma after allogeneic hematopoietic cell transplantation: a retrospective study of the EBMT Lymphoma Working Party	Bazarbachi, Ali	Beirut	Lebanon	oral	
73	Safety and Efficacy of Combination of Brentuximab Vedotin and Nivolumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412)	Diefenbach, Catherine	New York	USA	oral	
74	Interim results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma	Herrera, Alex	Duarte	USA	oral	
75	CLARITHROMYCIN AS A "REPURPOSING DRUG" AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL)	Ferreri, Andrés	Milano	Italy	oral	
76	A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients with Relapsed or Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)	Amengual, Jennifer	New York	USA	oral	
77	Canadian Cancer Trials Group (CCTG) LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant (ASCT) in relapsed/refractory diffuse large B cell lymphoma (RR-DLBCL) - Outcome of Ibrutinib + R-GDP	Kuruville, John	Kingston	Canada	oral	
78	EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.	Pettitt, Andrew	Liverpool	UK	oral	
79	Venetoclax (VEN), Bendamustine (B) and Rituximab (R) in Patients (Pts) with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Final Results of a Phase I Study	Swinnen, Lode	Baltimore	USA	oral	
80	Pola-R-CHP: polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, prednisone for patients with previously untreated diffuse large B-cell lymphoma	Tilly, Hervé	Rouen	France	oral	
81	Application of a gene expression-based model in combination with FDG-PET imaging to predict treatment response in advanced Hodgkin lymphoma in the RATHL study (CRUK/07/033)	Burton, Cathy	Leeds	UK	oral	
82	The 23-gene gene expression-based assay does not predict interim PET scan results after ABVD in advanced stage classical Hodgkin lymphoma in the US Intergroup S0816 trial.	Scott, David	Vancouver	Canada	oral	
83	Gene mutations and copy number alterations (CNA) predict for early failure in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP	Dlouhy, Ivan	Barcelona	Spain	oral	
84	KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL	Ferrero, Simone	Torino	Italy	oral	
85	Baseline circulating cell-free DNA load is related to, but adds prognostic value to metabolic tumor burden measured by FDG PET/CT in Follicular Lymphoma.	Delfau-Larue, Marie	CRETEIL	France	oral	
86	Evaluation of clinicogenetic risk models for outcome of follicular lymphoma patients in the PRIMA trial	Huet, Sarah	Pierre-Bénite	France	oral	
OT01	ROBUST: Phase III Randomized Study of Lenalidomide/R-CHOP vs Placebo/R-CHOP in Untreated ABC-Type Diffuse Large B-cell Lymphoma and Feasibility of Cell of Origin Subtyping	Chiappella, Annalisa	Torino	Italy	oral	
OT02	Phase II study of durvalumab (anti-PD-L1) combined with either R-CHOP or lenalidomide and R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma	Jaeger, Ulrich	Vienna	Austria	oral	
OT03	CheckMate 647: A Phase 2, Open-Label Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma or Relapsed/Refractory Primary Testicular Lymphoma	Nayak, Lakshmi	Boston	USA	oral	
OT04	MCL-R2 ELDERLY: A PHASE III STUDY of the <i>European MCL network</i> ASSESSING Efficacy of alternating immunochemotherapy (R-CHOP / R-HAD) and a rituximab-lenalidomide maintenance	Ribrag, Vincent	Villejuif	France	oral	
OT05	Title: Phase 3 Study of Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)	Tam, Constantine	Melbourne	Australia	oral	
OT06	A head-to-head phase 3 study comparing BGB-3111 and ibrutinib in patients with Waldenström macroglobulinemia	Buske, Christian	Ulm	Germany	oral	
87	Higher Age is Associated with Increased Mutational Burden but does Not Impact Treatment Efficacy in Follicular Lymphoma	Alig, Stefan	Munich	Germany	oral	
88	Low NK cell count at diagnosis is associated with shorter PFS in Elderly patients with DLBCL treated with RCHOP and randomized for Lenalidomide maintenance. A LYSA Study	DELFAU-LARUE, Marie	CRETEIL	France	oral	

89	CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP	Al-Sawaf, Othman	Cologne	Germany	oral	
90	Unmet medical needs in Hodgkin lymphoma with special focus on the elderly – A population-based study of patients diagnosed in Sweden 1973-2014	Björkholm, Magnus	Stockholm	Sweden	oral	
91	Treatment strategies and outcomes in diffuse large B-cell lymphoma of the elderly: A Danish population-based cohort study of 1,011 patients	Juul, Maja	Odense	Denmark	oral	
92	REMARC Study: Correlation of Lymphoma PD and Death and Health-Related QOL With Maintenance Lenalidomide vs Placebo in Elderly DLBCL Patient Responders to R-CHOP	Thieblemont, Catherine	Paris	France	oral	
93	A single-cell based model explains patterns of clonal evolution in primary and relapsed follicular lymphoma	Loeffler, Markus	Leipzig	Germany	oral	
94	Full transcriptome sequencing of sorted Hodgkin and Reed-Sternberg cells reveals plasmacytic differentiation, insights into mechanisms of oncogenesis and immune evasion	Roshal, Mikhail	New York	USA	oral	
95	Profiling of DNA methylation in epidemiological and clinical subgroups of Burkitt lymphoma in the framework of the MMMML, ICGC and BLUERPINT consortia	Wagener, Rabea	Ulm	Germany	oral	
96	Mutational Signatures in Germinal Center Derived B-Cell Lymphomas from Adult Patients analyzed in the ICGC MMMML-Seq consortium	Huebschmann, Daniel	Heidelberg	Germany	oral	
97	Cross-Platform Validation of Gene Expression Profiling (GEP) based Cell of Origin (COO) Classification in a clinical laboratory setting	Barrans, Sharon	Leeds	UK	oral	
98	The landscape of somatic mutations of primary cutaneous diffuse large B-cell lymphoma, leg-type	Jardin, Fabrice	Rouen	France	oral	
99	Inside-out VLA-4 integrin activation is maintained in ibrutinib-treated chronic lymphocytic leukemia expressing CD49d: clinical relevance	Tissino, Erika	Aviano	Italy	oral	
100	Integrated Analysis: outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) with high-risk prognostic factors	Kipps, Thomas	La Jolla	USA	oral	
101	Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: results of the GENUINE Phase 3 study	Mato, Anthony	Springfield	USA	oral	
102	Chemo-Free Triplet combination of TGR-1202, Ublituximab, and Ibrutinib is Well Tolerated and Highly Active in Patients with Advanced CLL and NHL.	Nastoupil, Loretta	Houston	USA	oral	
103	Safety and activity of the highly specific BTK inhibitor, BGB-3111 plus obinutuzumab in patients (pts) with follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)	Tam, Constantine	East Melbourne	Australia	oral	
104	Gene-expression profiling predicts disease progression in follicular lymphoma	Huet, Sarah	Pierre-Bénite	France	oral	
105	The Risk of Transformation of Follicular Lymphoma “Transformed” by Rituximab. The Aristotle Study promoted by the European Lymphoma Institute	Federico, Massimo	Modena	Italy	oral	
106	Prognostic model for high tumor burden follicular lymphoma including baseline Total Metabolic Tumor Volume and end induction PET: a pooled analysis from LYSA and FIL trials.	COTTEREAU, Anne-Ségolène	PARIS	France	oral	
107	Immunochemotherapy with obinutuzumab or rituximab in previously untreated follicular lymphoma in the randomised Phase III GALLIUM study: analysis by chemotherapy regimen	Hiddemann, Wolfgang	Munich	Germany	oral	
108	Coplanlisib in patients with relapsed or refractory indolent B-cell lymphoma (CHRONOS-1)	Dreyling, Martin	München	Germany	oral	
109	High response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an open-label, phase II study	Nastoupil, Loretta	Houston	USA	oral	
110	Non-Canonical Role of EZH2 in Natural Killer / T-cell Lymphoma	Chng, Wee	Singapore	Singapore	oral	
111	EBV-associated nodal T and NK-cell Lymphoma shows distinct molecular signature and copy number changes	Chng, Wee	Singapore	Singapore	oral	
112	NK/T-CELL LYMPHOMA: WHEN PATIENTS MEET OMICS	ZHAO, Wei Li	Shanghai	China	oral	
113	Treatment of extranodal NK/T-cell lymphoma, nasal type (ENKTL)	Kim, Won Seog	Seoul	Korea, Republic of	oral	
114	First-line L-asparaginase-based chemotherapy plus radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma: results from Peking University Cancer Hospital	Song, Yuqin	Beijing	China	oral	
115	Current treatment for NK/T Cell lymphoma: Sun Yat-sen University Cancer Center experience, China	Huang, Huiqiang	Guangzhou	China	oral	
116	Molecular characterization of extranodal natural killer (NK)/T-cell lymphomas, nasal type from Latin America	Quintanilla-Fend, Leticia	Tübingen	Germany	oral	
117	NK/T-cell lymphoma, the French experience	Jaccard, Arnaud	Limoges	France	oral	
118	Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma	Smedby, Karin	Solna	Sweden	oral	
119	R-CHOP +/-radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL): Final results of the prospective randomized phase III 02-03 trial from the LYSA/GOELAMS	Lamy, Thierry	Rennes	France	oral	
120	Radiotherapy to bulky disease PET-negative after immunochemotherapy can be spared in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL	Pfreundschuh, Michael	Homburg	Germany	oral	
121	Differential efficacy of bortezomib in subtypes of diffuse large B-cell lymphoma (DLBL): A prospective randomised study stratified by transcriptome profiling: REMoDL-B	Davies, Andrew	Southampton	UK	oral	
122	Prognostic impact of BCL2 and MYC expression and translocation in untreated DLBCL: results from the Phase III GOYA study	Sehn, Laurie	Vancouver	Canada	oral	
123	Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Updated Results of a Multicenter Prospective Phase II Study of DA-EPOCH-R	Dunleavy, Kieron	Bethesda	USA	oral	

124	CD27 stimulation enhances CD20 mAb therapy through activation of innate immunity	Lim, Sean	Southampton	UK	oral	
125	Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow-Up of the Phase 2 CheckMate 205 Trial	Fanale, Michelle	Houston	USA	oral	
126	Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 KEYNOTE-087 Study	Zinzani, Pier Luigi	Bologna	Italy	oral	
127	A Phase Ib Study Evaluating the Safety and Clinical Activity of Atezolizumab Combined With Obinutuzumab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)	Palomba, M.	New York, NY	USA	oral	
128	High CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001)	Abramson, Jeremy	Boston	USA	oral	
129	A Phase I Trial of 19-28z CAR-T cells Post-High Dose Therapy and Autologous Transplantation (HDT-ASCT) for Relapsed and Refractory (r/r) B-cell non-Hodgkin Lymphoma (B-NHL)	Sauter, Craig	New York	USA	oral	
130	P53 but not SOX11 IHC has prognostic value independent of MIPI and Ki-67 in prospective trials of the European-MCL Network	Aukema, Sietse	Kiel	Germany	oral	
131	First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: results of the BRIGHT 5-year follow-up study	Flinn, Ian	Nashville, Tennessee	USA	oral	
132	First line treatment by the RiBVD regimen elicits high clinical and molecular response rates and prolonged survival in elderly MCL patients; final results of a LYSA group trial	Gressin, Remy	GRENOBLE	France	oral	
133	Ibrutinib-Rituximab Followed by Reduced Chemo-immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: a Window of Opportunity to Reduce Chemo	Wang, Michael	Houston	USA	oral	
134	Ibrutinib vs Temozolimus: Three-year Follow-up of Patients With Previously Treated Mantle Cell Lymphoma from the Phase 3, International, Randomized, Open-Label RAY Study	Rule, Simon	Plymouth	UK	oral	
135	Combination Ibrutinib (Ibr) and Venetoclax (Ven) for the Treatment of Mantle Cell Lymphoma (MCL): Primary Endpoint Assessment of the Phase 2 AIM Study	Tam, Constantine	Melbourne	Australia	oral	
136	Interferon-Free Antiviral Treatment in B-cell Lymphoproliferative Disorders associated with Chronic Hepatitis-C Virus Infection	Frigeni, Marco	Pavia	Italy	oral	
137	Immunochemotherapy with obinutuzumab or rituximab in a subset of patients in the randomised GALLIUM trial with previously untreated marginal zone lymphoma (MZL)	Herold, Michael	Erfurt	Germany	oral	
138	Long-term results of the Multicenter Phase II Trial with Bendamustine and Rituximab as First Line Treatment for Patients with MALT Lymphoma (MALT-2008-01).	Salar, Antonio	Barcelona	Spain	oral	
139	Phase IIIb study of lenalidomide plus rituximab followed by maintenance in relapsed or refractory NHL: analysis of marginal zone lymphoma	Coleman, Morton	New York, NY	USA	oral	
140	Whole-exome-sequencing of nodal marginal zone lymphomas identifies recurrent molecular lesions in genes involved in chromatin remodelling and NOTCH signalling	Pillonel, Vincent	Basel	Switzerland	poster	Pathology
141	Integrative mutational analysis of Pediatric-Type Follicular Lymphoma reveals <i>TNFRSF14</i> and <i>MAP2K1</i> as the most frequently mutated genes	Schmidt, Janine	Tübingen	Germany	poster	Pathology
142	Down-regulation of miR-150 and up-regulation of its target FOXP1 is associated with transformation of follicular lymphoma	Musilova, Katerina	Brno	Czech Republic	poster	Pathology
143	NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY	Ferrero, Simone	Torino	Italy	poster	Pathology
144	Host Genetic Variation in the TNF and NF-κB Pathways and Prognosis in Mantle Cell Lymphoma: An Analysis of Two Studies	Wang, Yucai	Rochester	USA	poster	Pathology
145	High proliferation (MCL35 assay) is associated with inferior outcomes in patients treated with intensive regimens - a correlative study from the CALGB 50403 (Alliance) trial	Scott, David	Vancouver	Canada	poster	Pathology
146	ETS1 phosphorylation at Thr38 (pETS1) is associated with cell of origin (COO), cell cycle activation, and inferior outcome in diffuse large B cell lymphoma (DLBCL)	Chung, Elaine	Belinzona	Switzerland	poster	Pathology
147	DNMT3A-2 expression levels characterise diffuse large B-cell lymphoma with distinct methylation patterns and outcome	Kuhnl, Andrea	London	UK	poster	Pathology
148	Kras and Ago2 interaction promote initiation of plasmablastic lymphoma using an <i>in vivo</i> mouse transplant model	Thai, Kevin	Cambridge	USA	poster	Pathology
149	Comprehensive epigenetic and transcriptional survey of the "imprintome" in normal B-cells and germinal center derived B-cell lymphomas of the MMML and ICGC MMML-Seq networks	Bens, Susanne	Ulm	Germany	poster	Pathology
150	Gene expression profiling and mutation analysis can aid treatment decision making in aggressive B cell lymphoma patients	Burton, Cathy	Leeds	UK	poster	Pathology
151	Application of cell-of-origin subtypes determined by digital gene expression in HIV-related diffuse large B-cell lymphomas	Baptista, Maria-Joao	Badalona	Spain	poster	Pathology
152	BIODLCL04: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2 AND TP53 IN UNTREATED POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA.	Chiappella, Annalisa	Torino	Italy	poster	Pathology
153	Prognostic significance and correlation to gene expression profile of <i>EZH2</i> mutations in diffuse large B-cell lymphoma (DLBL) in two large prospective studies	Cummin, Thomas	Southampton	UK	poster	Pathology
154	Preliminary evidence of a molecular predictor of tazemetostat response, beyond EZH2 mutation, in NHL patients via characterization of archive tumor and circulating tumor DNA	Blakemore, Stephen	Cambridge	USA	poster	Pathology
155	Array-based DNA methylome analyses of primary lymphomas of the central nervous system	Vogt, Julia	Ulm	Germany	poster	Pathology

156	Tumor genomic copy number abnormalities analyzed by high resolution SNP array impact outcome of Primary CNS Lymphoma: a retrospective analysis on 68 patients	GHESQUIERES, Herve	Pierre Benite	France	poster	Pathology
157	Characterization of mediastinal lymphomas in female siblings and identification of <i>TIRAP</i> as a novel lymphoma risk gene	Burkhard, Regula	Bern	Switzerland	poster	Pathology
158	Prognostic value of immunohistochemical markers in stage III/IV classical Hodgkin Lymphoma treated frontline in the LYSA EORTC 20012 randomized protocol	CANIONI, Danielle	PARIS	France	poster	Pathology
159	Identification and characterisation of the lymphoma initiating cell (LIC) population in an ALCL mouse model	Illert, Anna	Freiburg	Germany	poster	Pathology
160	Oncogenic Activation of STAT3 Pathway Drives PD-L1 Expression in Natural Killer/T cell Lymphoma	Song, Tammy	Singapore	Singapore	poster	Pathology
161	SAMHD1 is frequently involved in T-cell Prolymphocytic Leukemia (T-PLL) pathogenesis	Johansson, Patricia	Essen	Germany	poster	Pathology
162	Tanslocations involving <i>CD28</i> are rare in peripheral T-cell lymphomas	Vallois, David	Lausanne	Switzerland	poster	Pathology
163	Integrative Analysis of Features Associated With TET2, IDH2, DNMT3A and RHOA mutations in Angioimmunoblastic T cell Lymphoma: A LYSA Study	Lemonnier, François	Créteil	France	poster	Pathology
164	Focal skeletal 18F-FDG uptake characterizes a subset of classical Hodgkin lymphoma patients with poor outcome - A Danish-Swedish study of 209 newly diagnosed patients	Pedersen, Mette	Aarhus	Denmark	poster	Hodgkin Lymphoma
165	Histological verification of positive positron emission tomography findings during the follow-up of patients with mediastinal lymphoma: large experience on 96 patients	Quirini, Federica	Bologna	Italy	poster	Hodgkin Lymphoma
166	SAFETY AND EFFICACY ANALYSIS OF ELDERLY PATIENTS TREATED WITHIN THE GATLA HL-05 CLINICAL TRIAL: PET adapted therapy after 3 cycles of ABVD for all stages of Hodgkin Lymphoma	Pavlovsky, Astrid	Buenos Aires	Argentina	poster	Hodgkin Lymphoma
167	Allogeneic transplantation in Hodgkin's lymphoma after a failed autograft: long term outcomes and graft-versus-host disease free/relapse-free survival (GRFS)	Spina, Francesco	Milan	Italy	poster	Hodgkin Lymphoma
168	Brentuximab-Vedotin and Bendamustine is a feasible and effective drug combination as first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).	Gallamini, Andrea	Nice	France	poster	Hodgkin Lymphoma
169	Real life experience with brentuximab vedotin: the Italian study on 234 relapsed/refractory Hodgkin's lymphoma	Pellegrini, Cinzia	Bologna	Italy	poster	Hodgkin Lymphoma
170	A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy followed by 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma	Kumar, Anita	New York, NY	USA	poster	Hodgkin Lymphoma
171	Outcomes of treatment for obese patients with advanced Hodgkin lymphoma in the RATHL trial (CRUK/07/033)	Preston, Andrea	Bristol	UK	poster	Hodgkin Lymphoma
172	Mortality rates remain increased in young patients with classical Hodgkin lymphoma even after years in remission: Results from a Nordic Lymphoma Group Study	Biccler, Jorne	Aalborg	Denmark	poster	Hodgkin Lymphoma
173	Predicted Cardiac and Second Cancer Risks in Hodgkin Lymphoma Patients Treated with Advanced Proton Beam Therapy Compared to Photon Radiotherapy.	Ntentas, Georgios	Oxford	UK	poster	Hodgkin Lymphoma
174	Cardiac disease prediction following Hodgkin lymphoma: An EORTC Lymphoma Group and GELA follow-up study	Maraldo, Maja	Copenhagen	Denmark	poster	Hodgkin Lymphoma
175	Usefulness of N-terminal brain natriuretic peptide levels and FRESCO scale for the prediction of anthracycline-induced cardiomyotoxicity in patients with Hodgkin Lymphoma	Ferraro, Mariana	Barcelona	Spain	poster	Hodgkin Lymphoma
176	Dose and/or Volume Reduction Using Consolidation Volume Radiation Therapy (CVRT) Lowers Dose to Heart and Lungs in Early-Stage Hodgkin Lymphoma Patients with Bulky Disease	Yang, Joanna	New York	USA	poster	Hodgkin Lymphoma
177	Overall and disease-specific survival of patients who survived Hodgkin lymphoma and developed gastrointestinal cancer	Van Leeuwen, Flora	Amsterdam	Netherlands	poster	Hodgkin Lymphoma
178	Autoimmune Disease (AID) is both a Risk Factor and a Prognostic Factor Affecting Survival in Patients with B-Cell Non-Hodgkin Lymphoma (NHL)	Paltiel, Ora	Jerusalem	Israel	poster	Aggressive Lymphomas
179	Microenvironmental features reflecting immunocompetence are strong outcome determinants in HIV-associated lymphoma	Vase, Maja	Aarhus	Denmark	poster	Aggressive Lymphomas
180	Outcome Prediction in Diffuse Large B-cell Lymphoma Can Be Greatly Improved by Alternative Use of Clinical Information: A Nordic Lymphoma Group Study	Biccler, Jorne	Aalborg	Denmark	poster	Aggressive Lymphomas
181	Simultaneous Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) at the Diagnosis has similar outcome as DLBCL	Benesova, Katerina	Prague	Czech Republic	poster	Aggressive Lymphomas
182	High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials	Reagan, Patrick	Rochester	USA	poster	Aggressive Lymphomas
183	LONG-TERM FOLLOW-UP AFTER LOCALIZED RADIOTHERAPY IN PATIENTS WITH TRANSFORMED B-CELL LYMPHOMA TREATED WITH RITUXIMAB-CONTAINING CHEMOTHERAPY	Nozaki, Kenji	Tokyo	Japan	poster	Aggressive Lymphomas
184	Obinutuzumab-miniCHOP for the Treatment of Elderly Unfit Patients with Diffuse Large B-Cell Lymphoma. A study of the Fondazione Italiana Linfomi.	Merli, Francesco	Reggio Emilia	Italy	poster	Aggressive Lymphomas
185	End of treatment PET-CT predicts progression free survival in DLBCL after first-line treatment: results from the Phase III GOYA study	Kostakoglu, Lale	New York	USA	poster	Aggressive Lymphomas
186	Rituximab SC and IV plus CHOP show similar efficacy and safety in the randomised MabEase study in first-line DLBCL	Lugtenburg, Pieterella	Rotterdam	Netherlands	poster	Aggressive Lymphomas
187	R-COMP vs. R-CHOP AS FIRST-LINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA IN PATIENTS OLDER THAN 60 YEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH GELTAMO GROUP	Sancho, Juan-Manuel	Badalona	Spain	poster	Aggressive Lymphomas
188	Anthracycline Dose Intensification in Diffuse Large B-cell Lymphoma	Zhao, Wei-li	Shanghai	China	poster	Aggressive Lymphomas
189	Phase 2 randomized trial comparing standard RCHOP versus BRCAp as first line treatment in young patients with high-risk DLBCL. A study from Spanish Group GELTAMO	Gonzalez-Barca, Eva	Barcelona	Spain	poster	Aggressive Lymphomas

190	Phase 1b study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rPMBCL): updated results from the KEYNOTE-013 trial	Zinzani, Pier Luigi	Bologna	Italy	poster	Aggressive Lymphomas
191	Rituximab, lenalidomide, and ibrutinib alone and combined with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma	Westin, Jason	Houston	USA	poster	Aggressive Lymphomas
192	Safety and Clinical Activity of Temozolomide in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma – Report of the prospective, multicenter Phase II STORM Trial	Witzens-Harig, Mathias	Heidelberg	Germany	poster	Aggressive Lymphomas
193	A Phase 2b Randomized Study of Single Agent Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Casasnovas, Rene-Olivier	Dijon	France	poster	Aggressive Lymphomas
194	Bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Final analysis of a phase 2 study from GELTAMO	Martín, Alejandro	Salamanca	Spain	poster	Aggressive Lymphomas
195	Reduced intensity (FB2) vs reduced toxicity myeloablative (FB3-4) fludarabine/busulfan based conditioning regimens for non-Hodgkin lymphoma (NHL) allografted patients.	Le Bourgeois, Amandine	Nantes	France	poster	Aggressive Lymphomas
196	Double-expressor lymphomas do not have inferior outcome after autologous stem cell transplant in the first line treatment.	Trnny, Marek	Praha	Czech Republic	poster	Aggressive Lymphomas
197	Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-associated Diffuse Large B-cell Lymphomas	Merli, Michele	Varese	Italy	poster	Aggressive Lymphomas
198	Current therapy of secondary CNS involvement in malignant lymphoma: Data from a multicenter prospective international registry	Korfel, Agnieszka	Berlin	Germany	poster	Aggressive Lymphomas
199	Validation of the CNS International Prognostic Index in a Large Asian Cohort – Data from the Singapore Lymphoma Study Group	Lee, Yuh Shan	Singapore	Singapore	poster	Aggressive Lymphomas
200	PROPHYLAXIS WITH HIGH-DOSE METHOTREXATE SIGNIFICANTLY REDUCES CNS DISSEMINATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND HIGH-RISK CNS-IPi SCORE	Ferreri, Andrés	Milano	Italy	poster	Aggressive Lymphomas
201	The 5-year follow-up results of the C5R protocol with rituximab and intrathecal liposomal cytarabine for Primary CNS Lymphoma: a prospective phase 2 study of the LYSA	Ghesquieres, Herve	Pierre Benite	France	poster	Aggressive Lymphomas
202	Dose-dense chemoimmunotherapy and CNS prophylaxis in patients with high-risk DLBCL: a comparison of Nordic CRY-04 and CHIC studies	Leppä, Sirpa	Helsinki	Finland	poster	Aggressive Lymphomas
203	Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy	Murawski, Niels	Homburg	Germany	poster	Aggressive Lymphomas
204	Frequency of perforation & impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement: an international, multicenter retrospective study.	Chin, Collin	Nedlands	Australia	poster	Aggressive Lymphomas
205	Long Term Follow-Up Update for Patients Enrolled in ECOG 1405	Khan, Nadia	Philadelphia	USA	poster	Mantle Cell Lymphoma
206	Mantle cell lymphoma of mucosa associated lymphoid tissue: a retrospective multicenter observational study of the European Mantle Cell Lymphoma Network	Morello, Lucia	Rozzano (MI)	Italy	poster	Mantle Cell Lymphoma
207	Venetoclax (VEN) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)	Davids, Matthew	Boston	USA	poster	Mantle Cell Lymphoma
208	R-CHOP / R-HDAC and rituximab maintenance results in high complete remission rate, minimal residual disease negativity, and excellent survival in elderly MCL patients	Klener, Pavel	Prague 2	Czech Republic	poster	Mantle Cell Lymphoma
209	Maintenance rituximab improves survival in newly diagnosed mantle cell lymphoma patients: analysis of the Czech Lymphoma Study Group	Obr, Aleš	Olomouc	Czech Republic	poster	Mantle Cell Lymphoma
210	Rituximab Maintenance after Nordic Protocol (R-MaxiCHOP/HD-AraC/ASCT) Significantly Prolongs Survival in Young Mantle Cell Lymphoma Patients	Klener, Pavel	Prague	Czech Republic	poster	Mantle Cell Lymphoma
211	SAKK 36/13 - Ibrutinib and bortezomib followed by ibrutinib maintenance in patients with relapsed and refractory mantle cell lymphoma: Phase I report of a Phase I/II trial	Novak, Urban	Bern	Switzerland	poster	Mantle Cell Lymphoma
212	Phase I/II clinical trial of an activated whole tumor cell vaccine followed by transfer of immune T cells in patients with mantle cell lymphoma	Frank, Matthew	Stanford	USA	poster	Mantle Cell Lymphoma
213	Obinutuzumab plus ibrutinib in relapse/refractory mantle cell lymphoma patients: first results of the Oasis phase I trial.	Le Gouill, Steven	Nantes	France	poster	Mantle Cell Lymphoma
214	Rituximab maintenance after autologous stem cell transplantation in patients with mantle cell lymphoma, final result of the LyMa trial conducted on behalf the LYSA group	Le Gouill, Steven	Nantes	France	poster	Mantle Cell Lymphoma
215	Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study	Fowler, Nathan	Houston	USA	poster	Indolent Lymphoma
216	Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): a multicenter, open-label, phase 2 study	Collins, Graham	Oxford	UK	poster	Indolent Lymphoma
217	Progression-free survival following lenalidomide-based treatment is significantly longer in extragastric than in gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)	Kiesewetter, Barbara	Vienna	Austria	poster	Indolent Lymphoma
218	Beyond Maximum Grade: A Novel, Longitudinal Toxicity Over Time (ToxT) Adverse Event Analysis of Lenalidomide in Follicular Lymphoma in CALGB 50401 (Alliance)	Thanarajasingam, Gita	Rochester	USA	poster	Indolent Lymphoma
219	Treatment with combination of lenalidomide and rituximab achieves durable responses in a long term follow up of patients with indolent non-hodgkin's lymphoma	Chaudhry, Maria	Houston	USA	poster	Indolent Lymphoma
220	Minimal residual disease and outcomes in relapsed/refractory follicular lymphoma (FL) in the Phase III GADOLIN trial of obinutuzumab and bendamustine vs bendamustine	Pott, Christiane	Kiel	Germany	poster	Indolent Lymphoma
221	R-CP chemoimmunotherapy in patients with IgM paraproteinaemic neuropathy produces improvements in functional, electrophysiological and serological outcomes.	Duncombe, Andrew	Southampton	UK	poster	Indolent Lymphoma
222	Bendamustine-rituximab (BR) versus R-CHOP as upfront therapy for indolent B-cell lymphomas: a comparative, population-based analysis	Olszewski, Adam	Providence	USA	poster	Indolent Lymphoma

223	A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED-STAGE FOLLICULAR LYMPHOMA	Buske, Christian	Ulm	Germany	poster	Indolent Lymphoma
224	Characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era	SESQUES, PIERRE	PIERRE BENITE	France	poster	Indolent Lymphoma
225	Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or immunochemotherapy in Follicular Lymphoma	Jiménez Ubieto, Ana	MADRID	Spain	poster	Indolent Lymphoma
226	"Autologous transplantation improves survival in patients with follicular lymphoma experiencing early therapy failure after frontline chemoimmunotherapy: A NLCS and CIBMTR analysis"	Casulo, Carla	Rochester	USA	poster	Indolent Lymphoma
227	Minimal residual disease (MRD) in early stage follicular lymphoma can predict prognosis and drive rituximab treatment after radiotherapy	Pulsoni, Alessandro	Rome	Italy	poster	Indolent Lymphoma
228	Low Grade B-cell Non-Hodgkin Lymphomas involving the Central Nervous System: An Analysis from the National Cancer Database	Pophali, Priyanka	Rochester	USA	poster	Indolent Lymphoma
229	Clinical characteristics and treatment outcomes for young patients with first-line follicular lymphoma: a pooled analysis of 4249 patients from the FLASH database.	Fornecker, Luc-Matthieu	Strasbourg	France	poster	Indolent Lymphoma
230	Patients with follicular lymphoma (FL) in maintained complete response (CR) at 30 months show a survival similar to a sex- and age-matched Spanish general population	Magnano, Laura	Barcelona	Spain	poster	Indolent Lymphoma
231	POD24 and CR30 are promising surrogate endpoints for assessing the outcome of patients with advanced stage Follicular Lymphoma enrolled in the FOLL05 trial by FIL.	Luminari, Stefano	Reggio Emilia	Italy	poster	Indolent Lymphoma
232	Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed Follicular lymphoma in the Rituximab era	Batlevi, Connie	New York	USA	poster	Indolent Lymphoma
233	Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma	Soumerai, Jacob	New York	USA	poster	Indolent Lymphoma
234	Statin use and prognosis in 12,865 non-Hodgkin lymphoma patients treated in the Rituximab-era	Brånvall, Elsa	Stockholm	Sweden	poster	Indolent Lymphoma
235	Ibrutinib Increases the Systemic Exposure of Rituximab: Pharmacokinetic Results from the HELIOS Trial	Cramer, Paula	Cologne	Germany	poster	CLL
236	Effect of single-agent ibrutinib on tumor debulking and reductions in tumor lysis syndrome (TLS) risk in patients (pts) with chronic lymphocytic leukemia (CLL)	Tam, Constantine	Melbourne	Australia	poster	CLL
237	High overall response rate with the BTK inhibitor BGB-3111 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: an update on safety and activity	Seymour, John	East Melbourne	Australia	poster	CLL
238	Long-term Efficacy and Safety in the RESONATE Study: Ibrutinib in Patients With Previously-Treated Chronic Lymphocytic Leukemia (CLL) With Up to Four Years Follow-up	Montillo, Marco	Milano	Italy	poster	CLL
239	Outcomes with Bruton Tyrosine Kinase Inhibition in relapsed / refractory chronic lymphocytic leukemia / small lymphocytic lymphoma after progression on venetoclax	Anderson, Mary Ann	Melbourne	Australia	poster	CLL
240	Outcomes of patients post ibrutinib treatment for relapsed / Refractory CLL: A UK and Ireland analysis	Follows, George	Cambridge	UK	poster	CLL
241	Ibrutinib For Relapsed / Refractory CLL: An update of the UK And Ireland Analysis Of Outcomes In 315 Patients	Follows, George	Cambridge	UK	poster	CLL
242	Redefining the role of etoposide in peripheral T-cell lymphoma treatment	Koh, Youngil	Seoul	Korea, Republic of	poster	NK and T-cell Lymphomas
243	Prognostic factors and impact of etoposide in adults with systemic ALK-positive anaplastic large-cell lymphoma: a pooled analysis of six studies	Sibon, David	Paris	France	poster	NK and T-cell Lymphomas
244	Outcome of patients with relapsed and refractory peripheral T cell lymphoma intended for stem cell transplant	Parkin, Stephen	Vancouver	Canada	poster	NK and T-cell Lymphomas
245	A multi-center study of GLIDE chemotherapy consolidated with autologous stem cell transplantation for newly diagnosed stage IV and relapsed extranodal natural killer/T-cell lymphoma patients	Ji, Jie	Chengdu	China	poster	NK and T-cell Lymphomas
246	Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (R/R sALCL). A Retrospective Analysis of the Lymphoma Working Party-EBMT.	Domingo Domenech, Eva	Hospitalet de Llobregat	Spain	poster	NK and T-cell Lymphomas
247	Risk stratification based on NCCN-IPI at the time of diagnosis in combination with post-treatment PET-CT scan for the treatment of nodal peripheral T-cell lymphoma	Yhim, Ho-Young	Jeonju	Korea, Republic of	poster	NK and T-cell Lymphomas
248	The role of 18F FDG-PET/CT in peripheral T-cell lymphoma (PTCL): initial results of the UK NCRI multicentre phase II randomised CHEMO-T trial PET/CT substudy	Gleeson, Mary	Sutton	UK	poster	NK and T-cell Lymphomas
249	Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study	Horwitz, Steven	New York	USA	poster	NK and T-cell Lymphomas
250	Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the Phase 3 ALCANZA study	Prince, H.	Melbourne	Australia	poster	NK and T-cell Lymphomas
251	A phase 1/2 study of brentuximab vedotin in pediatric patients with relapsed/refractory (R/R) systemic anaplastic large-cell lymphoma (sALCL) or R/R Hodgkin lymphoma (HL)	Locatelli, Franco	Rome	Italy	poster	NK and T-cell Lymphomas
252	Prognostic factors in patients with relapsed or refractory systemic anaplastic large T-cell lymphoma (ALCL) receiving brentuximab vedotin and outcome after treatment failure.	Okii, Yasuhiro	Houston	USA	poster	NK and T-cell Lymphomas
253	Case Match Control Analysis of PROPEL Reveals a Survival Advantage for Patients with Relapsed PTCL Receiving Pralatrexate: A Novel Approach to Benchmark Drugs in Rare Diseases	O'Connor, Owen	New York	USA	poster	NK and T-cell Lymphomas

254	A Post-marketing Surveillance Study of 703 Patients Treated with Chidamide for Peripheral T-cell Lymphoma (PTCL) in China HDAC Study Group of Union for China Lymphoma Investigators(UCLI)	MA, JUN	Harbin	China	poster	NK and T-cell Lymphomas
255	Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma.	Witzig, Thomas	Rochester	USA	poster	NK and T-cell Lymphomas
256	Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: Interim results of postmarketing all-case surveillance	Ishitsuka, Kenji	Kagoshima	Japan	poster	NK and T-cell Lymphomas
257	Targeting the T-cell receptor β -constant domain for immunotherapy of T-cell malignancies	Maciocia, Paul	London	UK	poster	NK and T-cell Lymphomas
258	Development of novel, non-toxic rifamycins that reverse drug resistance in diffuse large B-cell lymphoma (DLBCL)	Maxwell, Steve	College Station	USA	poster	New drug development
259	Development of novel preclinical models of secondary resistance to the PI3K δ inhibitor idelalisib in splenic marginal zone lymphoma (SMZL)	Arribas, Alberto	Bellinzona	Switzerland	poster	New drug development
260	Dual inhibition of EZH2 and HDAC is synergistic in EZH2 dysregulated lymphomas	Lue, Jennifer	New York	USA	poster	New drug development
261	STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMAS (NHL)	Molina, Arturo	South San Francisco	USA	poster	New drug development
262	Combinatorial screening of the PI3K inhibitor copanlisib in T cell lymphomas	Gaudio, Eugenio	Bellinzona	Switzerland	poster	New drug development
263	Copanlisib in combination with anti-PD-1 induces regression in animal tumor models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors	Liu, Ningshu	Berlin	Germany	poster	New drug development
264	PD-1 immune checkpoint blockade improves anti-CD20 based immunotherapy in follicular lymphoma	Rossi, Cedric	toulouse	France	poster	New drug development
265	Novel targeted strategies to overcome microenvironment-dependent resistance in Mantle Cell Lymphoma	Chiron, David	Nantes	France	poster	New drug development
266	Effective therapy by anti-CD81 against B cell lymphomas engages both direct and indirect immune mechanisms	Levy, Shoshana	Stanford	USA	poster	New drug development
267	A phase I study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with rituximab in patients with CD20 ⁺ non-Hodgkin's lymphoma	Gopal, Ajay K	Seattle, WA	USA	poster	New drug development
268	Expression of LAG-3 defines exhaustion of intratumoral PD-1 ⁺ T cells and correlates with poor outcome in follicular lymphoma	Yang, Zhizhang	Rochester	USA	poster	New drug development
269	A dual targeting CAR-T cell approach for the treatment of B cell malignancies	Thomas, Simon	London	UK	poster	New drug development
270	Low Levels of Immuno-suppressor Cells Promote Responses to a Haploidentical Natural Killer Cell Therapy and Induce Remissions in Non-Hodgkin Lymphoma	Bachanova, Veronika	Minneapolis	USA	poster	New drug development
271	A phase I study of chimeric antigen receptormodified T cells directed against CD19 in patients with relapsed or refractoryCD19(+) B cell Lymphomas: interim analysis	Ying, Zhitao	Beijing	China	poster	New drug development
272	Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)	Neelapu, Sattva	Houston	USA	poster	New drug development
273	Safety and Clinical Activity of RP6530, a Dual PI3K δ / γ Inhibitor, in Patients with advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multi-center Study	Carlo-Stella, Carmelo	Milano	Italy	poster	New drug development
274	A Phase 1 Study of BET Inhibition Using RG6146 in Relapsed/Refractory (R/R) MYC-expressing Diffuse Large B Cell Lymphoma (DLBCL)	Caimi, Paolo	Cleveland	USA	poster	New drug development
275	A Phase I Study of Ibrutinib Combined with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma	Sauter, Craig	New York	USA	poster	New drug development
276	Preliminary Results of a Phase 1b Study of Tirabrutinib (GS-4059/ONO-4059) in Combination with Entospletinib in Patients with B-cell Malignancies.	Morschhauser, Franck	Lille	France	poster	New drug development
277	Combination of TGR-1202, Ublituximab, and Bendamustine is Safe and Highly Active in Patients with Advanced DLBCL and Follicular Lymphoma.	Lunning, Matthew	Omaha	USA	poster	New drug development
278	Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-cell Lymphoma: Phase I/II Results	Westin, Jason	Houston	USA	poster	New drug development
279	Ongoing Phase 1/2 Study of INCB050465, a Selective PI3K δ Inhibitor, for the Treatment of Patients (Pts) With Relapsed/Refractory (R/R) B-Cell Malignancies (CITADEL-101)	Caimi, Paolo	Cleveland, OH	USA	poster	New drug development
280	The Immunologic Doublet of Lenalidomide Plus Obinutuzumab is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/II Study	Fowler, Nathan	Houston	USA	poster	New drug development
281	Integrated safety data with copanlisib monotherapy from phase I and II trials in patients with relapsed indolent non-Hodgkin's lymphoma	Zinzani, Pier Luigi	Bologna	Italy	poster	New drug development
282	LYMRIT 37-01: Updated results of a phase I/II study of ¹⁷⁷ Lu-lilotomab satetraxetan, a novel CD37-targeted antibody- radionuclide-conjugate in relapsed NHL patients	Kolstad, Arne	Oslo	Norway	poster	New drug development
283	Interim Data from the First Clinical Study of ADCT-301, a Novel Pyrrolobenzodiazapine-Based Antibody Drug Conjugate, in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma	Horwitz, Steve	New York	USA	poster	New drug development
284	Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: updated results of a phase 1b/2 study	Matasar, Matthew	New York, NY	USA	poster	New drug development
285	YourTreatmentChoices: Fast Access to Trials Programme	Radford, John	Manchester	UK	poster	New drug development
286	Increasing cross-referral and recruitment to clinical trials: a new APPROach	Trotman, Judith	Sydney	Australia	poster	New drug development
287	Oral Azacytidine (AZA) and Romidepsin (R) Reveals Promising Activity in Patients with Relapsed or Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)	O'Connor, Owen	New York	USA	poster	New drug development
288	CD70 expression in Cutaneous T cell lymphoma (CTCL) patients and mechanisms of action of ARGX-110 in skin: histopathological and clinical data	Hultberg, Anna	Zwijnaarde	Belgium	poster	New drug development
289	Ph 1 Trial Evaluating MRG-106, a microRNA-155 Inhibitor, Administered By Intratumoral, Subcutaneous, or Intravenous Delivery in Cutaneous T-cell Lymphoma (CTCL) Patients	Querfeld, Christiane	Duarte	USA	poster	New drug development

290	Quantitative analysis of MYD88 L265P Mutations by digital PCR is an independent prognostic factor for CNS relapse as well as systemic relapse and poor outcome	NISHIMURA, NORIKO	Tokyo	Japan	publication	Biology
291	High prevalence and clinical significance of oncogenic <i>CD79B</i> and <i>MYD88</i> mutations in primary testicular diffuse large B-cell lymphoma: A retrospective study in China	Chen, Yanping	Fuzhou	China	publication	Biology
292	Molecular analysis of primary cutaneous diffuse large B-cell lymphoma, leg type	Goodlad, John	Leeds	UK	publication	Biology
293	Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma	Pan-Hammarstrom, Qiang	Stockholm	Sweden	publication	Biology
294	Molecular Landscape of Relapse/Refractory Diffuse Large B Cell Lymphoma.	Michot, Jean-Marie	Villejuif	France	publication	Biology
295	Genetic heterogeneity in B-cell lymphoma detected by next-generation sequencing (NGS) technology in a cohort of 150 Chinese patients	Chen, Yanping	Fuzhou	China	publication	Biology
296	Identifying somatic mutations in cell free DNA of aggressive Lymphoma patients: first cell free DNA results from the Molecular profiling for Lymphoma (MaPLe) study.	Lopez Pascua, Laura	Oxford	UK	publication	Biology
297	Comprehensive Characterization of Mutations, Gene Expression and Immune Repertoires in Malignant Lymphoma by Anchored Multiplex PCR and Next-Generation Sequencing	Fugere, Darius	Boulder	USA	publication	Biology
298	Klotho Suppresses Tumor Growth of T-cell Lymphoma via Inhibiting IGF-1R signaling	Zhou, Xiangxiang	Jinan	China	publication	Biology
299	Metadherin promotes the invasiveness of diffuse large B cell lymphoma	Li, Ying	Jinan	China	publication	Biology
300	Whole-Exome analysis of abnormalities leading to Waldenström's Macroglobulinemia transformation into aggressive lymphoma	Alcoceba, Miguel	Salamanca	Spain	publication	Biology
301	Identification and gene expression analysis of the side population subclone in mantle cell lymphoma	Ek, Sara	Lund	Sweden	publication	Biology
302	NPM1-ALK OVEREXPRESSION-DRIVEN TOXICITY IN ALCL IS PARTNER DEPENDENT AND DRIVEN BY PHOSPHORYLATION OF NOVEL SUBSTRATES LEADING TO OVERSTIMULATION OF BIOSYNTHETIC PATHWAYS	Schatz, Jonathan	Miami	USA	publication	Biology
303	mir146-b expression levels correlate with biological and clinical features in T-LGL Leukemia	Zambello, Renato	Padua	Italy	publication	Biology
304	FOLLICULAR LARGE CLEAVED CELL (CENTROCYTIC) LYMPHOMA: A DISTINCTIVE BUT UNRECOGNIZED VARIANT OF FOLLICULAR LYMPHOMA	Weisenburger, Dennis	Duarte	USA	publication	Pathology
305	Unfavorable Prognostic Impact of MYC Increased Copy Number (ICN) in Patients with Diffuse Large B-Cell (DLBCL) and High-Grade Lymphoma Treated with Immuno-Chemotherapy	Schieppati, Francesca	Brescia	Italy	publication	Pathology
306	PROGNOSTIC IMPACT OF "MYC/BCL-2 DOUBLE EXPRESSORS" IN DIFFUSE LARGE B-CELL LYMPHOMA	Ferrer Lores, Blanca	Valencia	Spain	publication	Pathology
307	BCL2 mRNA or protein abundance is superior to gene rearrangement status in predicting clinical outcomes in patients with diffuse large B-cell lymphoma	Li, Yi	Kingston	Canada	publication	Pathology
308	The clinical significance of c-MYC expression, rearrangement, and copy number gain in extranodal NK/T-cell lymphoma: A retrospective study in China	Chen, Yan-ping	Fuzhou	China	publication	Pathology
309	CD30 Expression in Diffuse Large B-Cell Lymphoma Correlates with Non-GCB Subtype but Does Not Have Prognostic Impact in Patients Treated with First Line R-CHOP/R-CHOP-like	Salas, Queralt	Barcelona	Spain	publication	Pathology
310	Analysis of preclinical and clinical samples after treatment with a CD37 targeting Antibody Drug Conjugate (AGS67E) support a high level of CD37 expression in NHL	Doñate, Fernando	Santa Monica	USA	publication	Pathology
311	Role of Genetic Polymorphisms on R-CHOP efficacy in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study	Rigacci, Luigi	Firenze	Italy	publication	Pathology
312	MELK serves as a Potent Independent Biomarker to Predict Survival of Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP Regimen	Zhang, Ya	Jinan	China	publication	Pathology
313	BMI-1 protein expression as a negative independent prognostic factor in DLBCL	Pedersen, Mette	Herlev	Denmark	publication	Pathology
314	Role of the abnormal HIF-1 α -Glycolysis-Aerobic Oxidation pathway in non-Hodgkin Lymphoma and the intervention study	WANG, Ting	Shanghai	China	publication	Pathology
315	Cytoplasmatic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival.	Neumeister, Peter	Graz	Austria	publication	Pathology
316	Tumor necrosis as a prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP therapy	CHUNG, Joo-seop	Busan	Korea, Republic of	publication	Pathology
317	MICROENVIRONMENT ESPRESSION IN DIFFUSE LARGE B CELL LYMPHOMAS	Gaudio, Francesco	Bari	Italy	publication	Pathology
318	EBV infection promotes tumor infiltrating leucocyte and immune escape in plasmablastic lymphoma according to gene expression profiling.	Laurent, Camille	Toulouse	France	publication	Pathology
319	ARE DIFFERENCES BETWEEN PEDIATRIC EBV-ASSOCIATED LYMPHOMAS AND CARRIERS REGARDING LATENCY PROFILE AND MICROENVIRONMENT COMPOSITION INVOLVED IN LYMPHOMAGENESIS?	Cohen, Melina	Buenos Aires	Argentina	publication	Pathology
320	Histopathological and immunohistochemical study of malignant lymphomas	Jiménez Galainena, Julio	Havana City	Cuba	publication	Pathology
321	Pan-lymphoma classification	Bentley, Michael	Leeds	UK	publication	Pathology
322	MINIMAL RESIDUAL DISEASE BY NEXT-GENERATION SEQUENCING IN MANTLE CELL LYMPHOMA: THE BIOINFORMATICS TOOL HASHCLONE	Genuardi, Elisa	Torino	Italy	publication	Pathology
323	PET-CT Adapted therapy for advanced Hodgkin Lymphoma: a systematic review of the literature	Amitai, Irina	Petah Tikva	Israel	publication	PET Imaging
324	Preliminary results of a phase II study using response-adapted therapy for limited stage diffuse large B-cell lymphoma based on interim PET/CT	Lv, Fangfang	Shanghai	China	publication	PET Imaging
325	Prognostic significance of interim ¹¹ C-methionine PET for the treatment of primary central nervous system lymphoma (PCNSL)	Yang, Deok-Hwan	Jeonnam	Korea, Republic of	publication	PET Imaging
326	HISTOLOGICAL VALIDATION BY IMAGING-GUIDED CORE-NEEDLE-CUTTING BIOPSY OF 4 TO 5 POINT SCALE DEAUVILLE CRITERIA (DC): RETROSPECTIVE ANALYSIS IN HODGKING LYMPHOMA AT RESTAGING	Della Pepa, Roberta	Naples	Italy	publication	PET Imaging

327	Visual versus Metabolic Tumour Volume Assessments as Predictors for Outcome in Patients with Diffuse Large B-Cell Lymphoma: A single Site Retrospective Study in 118 patients	Gormsen, Lars	Aarhus C	Denmark	publication	PET Imaging
328	Utility of baseline assessment with FDG-PET-CT compared with CT scanning in people with diffuse large B-cell lymphoma (DLBCL)	Cuadrado, Maria	London	UK	publication	PET Imaging
329	Whole-Body Diffusion-weighted MR Imaging in Lymphoma surveillance	Rademaker, Jürgen	New York, NY	USA	publication	PET Imaging
330	Noninvasive Prenatal Testing and Incidental Detection of maternal Hodgkin's Lymphoma	Balova, Veronika	Baden	Switzerland	publication	Hodgkin Lymphoma
331	Alcohol induced pain and pruritus in Hodgkin lymphoma	Molin, Daniel	Uppsala	Sweden	publication	Hodgkin Lymphoma
332	20 year follow up of Hodgkin Lymphoma: predictors of survival and secondary malignancies.	Vallansot, Rolando	Tarragona	Spain	publication	Hodgkin Lymphoma
333	The Importance of Physical Activity in Adult Lymphoma Survivors - single center's experience with the supervised aerobic and resistance training program	Hadrabova, Marketa	Brno	Czech Republic	publication	Hodgkin Lymphoma
334	Prognostic significance of tryptophan catabolism in newly diagnosed Hodgkin lymphoma.	Masaki, Ayako	Nagoya	Japan	publication	Hodgkin Lymphoma
335	Treatment outcomes for Hodgkin's Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin's Lymphoma Registry	BIASOLI, IRENE	RIO DE JANEIRO	Brazil	publication	Hodgkin Lymphoma
336	Attendance to Hodgkin lymphoma survivorship care clinics in the Netherlands	Aleman, Berthe	Amsterdam	Netherlands	publication	Hodgkin Lymphoma
337	Outcome predictors in elderly Hodgkin's lymphoma patients Placeholder	Aviri, Irit	Tel Aviv	Israel	publication	Hodgkin Lymphoma
338	25(OH)Vitamin D serum levels associate with patient characteristics and outcome in Hodgkin Lymphoma	Cuccaro, Annarosa	Rome	Italy	publication	Hodgkin Lymphoma
339	IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION	Pugliese, Novella	Naples	Italy	publication	Hodgkin Lymphoma
340	Long-term quality of life in patients with advanced Hodgkin lymphoma: a systematic review	Dalal, Mehul	Cambridge	USA	publication	Hodgkin Lymphoma
341	Assessment and follow up of bone mineral density using CT attenuation measurements in Hodgkin lymphoma patients	Cohen, Bar	Jerusalem	Israel	publication	Hodgkin Lymphoma
342	SECOND MALIGNANCIES AND CARDIOVASCULAR DISEASES IN LONG-TERM HODGKIN LYMPHOMA SURVIVORS: THE ISTITUTO NAZIONALE TUMORI OF MILAN (INT) EXPERIENCE	Viviani, Simonetta	Milan	Italy	publication	Hodgkin Lymphoma
343	Patients with classical Hodgkin Lymphoma (cHL) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation.	Zaucha, Jan	Gdynia	Poland	publication	Hodgkin Lymphoma
344	Chemotherapy or Combined Modality Therapy for Early-Stage Hodgkin Lymphoma	Kelsey, Christopher	Durham	USA	publication	Hodgkin Lymphoma
345	CHEMOTHERAPY AND RADIATION IMPROVE SURVIVAL IN EARLY STAGE CLASSICAL HODGKIN LYMPHOMA:A STATEWIDE CANCER REGISTRY ANALYSIS.	Shrestha, Runa	Lexington	USA	publication	Hodgkin Lymphoma
346	EXCELLENT OUTCOME IN HODGEKIN LYMPHOMA WITH ABVD AND CMT: A SINGLE-CENTRE RETROSPECTIVE ANALYSIS	Bhatwadekar, Seema	Vadodara	India	publication	Hodgkin Lymphoma
347	Combination of idarubicin, vinblastine, dacarbazine, and gemcitabine (IVDG) as therapy for elderly patients with Hodgkin lymphoma with cardiac and pulmonary comorbidity	Kaplanov, Kamil	Volgograd	Russian Federation	publication	Hodgkin Lymphoma
348	HIGH-DOSE BENDAMUSTINE PLUS BRENTUXIMAB COMBINATION IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF REFRACTORY AND RELAPSED HODGKIN LYMPHOMA	Cerchione, Claudio	Napoli	Italy	publication	Hodgkin Lymphoma
349	Advanced Hodgkin Lymphoma in the East of England Cancer Network: a 10-year comparative analysis of outcomes for ABVD and escalated-BEACOPP treated patients aged 16–59	Russell, James	Cambridge	UK	publication	Hodgkin Lymphoma
350	Brentuximab vedotin and bendamustine as salvage therapy for primary refractory or relapsed Hodgkin lymphoma: a multicentre experience of the Polish Lymphoma Research Group	Czyz, Anna	Poznan	Poland	publication	Hodgkin Lymphoma
351	High response rates and safe toxic profile of Brentuximab vedotin/Bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin Lymphoma (HL)	Wannesson, Bruno	Buenos Aires	Argentina	publication	Hodgkin Lymphoma
352	Brentuximab Vedotin: a retrospective multicenter analysis of its indication, safety and efficacy in Argentina.	Negri Aranguren, Maria	Parana	Argentina	publication	Hodgkin Lymphoma
353	Nivolumab for relapsed or refractory Hodgkin lymphoma: experience in Turkey	Ferhanoglu, Burhan	Istanbul	Turkey	publication	Hodgkin Lymphoma
354	Outcomes of allogeneic hematopoietic stem cell transplantation (allo-SCT) for Hodgkin's Lymphoma: a single institution experience	Fiad, Nancy	Buenos Aires	Argentina	publication	Hodgkin Lymphoma
355	ACHIEVEMENT OF COMPLETE REMISSION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IS STRONGLY CORELATED WITH IMPROVED SURVIVAL OF PATIENTS WITH HODGKIN LYMPHOMA	Todorovic Balint, Milena	Belgrade	Serbia	publication	Hodgkin Lymphoma
356	Serum Biomarkers TARC and IL-6 Predict Relapse Risk in Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation	Bachanova, Veronika	Minnesota	USA	publication	Hodgkin Lymphoma
357	The Clinical outcome and Prognosis of Pediatric Mature B cell Lymphoma	Hong, Zhang	Beijing	China	publication	Aggressive Lymphomas
358	The prognostic implication of the pretreatment nutritional status in diffuse large B-cell lymphoma patients treated with rituximab based chemotherapy	Lee, Ji Hyun	Busan	Korea, Republic of	publication	Aggressive Lymphomas
359	Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Patients with Primary Central Nervous System Lymphoma	Eom, Hyeon-Seok	Goyang	Korea, Republic of	publication	Aggressive Lymphomas
360	A category-free approach to prognostic modelling in aggressive non-Hodgkin B cell lymphomas based on large patient databases	Burton, Cathy	Leeds	UK	publication	Aggressive Lymphomas
361	Grade 1-2 Neutropenia After First treatment for Diffuse Large B-cell Lymphoma is Associated with a Better Outcome Compared to grade 3-4 – A Danish Population-Based Cohort Study	Clausen, Michael	Aarhus	Denmark	publication	Aggressive Lymphomas
362	CARDIAC LYMPHOMAS: INCIDENCE AND OUTCOME IN NEWLY DIAGNOSED NON-HODGKIN'S LYMPHOMAS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) DATABASE.	Janikova, Andrea	Brno	Czech Republic	publication	Aggressive Lymphomas

363	Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma	Kusano, Yoshiharu	Tokyo	Japan	publication	Aggressive Lymphomas
364	Epstein-Barr virus load in plasma is an early biomarker of HIV-related lymphomas	Baptista, Maria-Joao	Badalona	Spain	publication	Aggressive Lymphomas
365	The negative prognostic significance of serum immunoglobulin paraprotein in patients with diffuse large B cell lymphoma	Xu, Wei	Nanjing	China	publication	Aggressive Lymphomas
366	Consolidation radiotherapy doesn't improve the outcome as compared with chemotherapy alone in patients with limited stage diffuse large B-cell lymphoma of Waldeyer's ring	Li, Chunyan	Shanghai	China	publication	Aggressive Lymphomas
367	Treatment outcomes using involved field and involved site radiotherapy for NHL and HL: Retrospective analysis from a large UK radiotherapy centre.	Jayalathike, Devinda	Birmingham	UK	publication	Aggressive Lymphomas
368	R-CHOP is not effective regimen in CD5(+)DLBCL diagnosed by flow-cytometry/immunohistochemistry, karyotype and BCL2/BCL6 status and expression.	Rymkiewicz, Grzegorz	Warsaw	Poland	publication	Aggressive Lymphomas
369	Response of Diffuse Large B-Cell Lymphoma treated with R-CHOP and prognostic factors associated: a single institution analysis in Lima, Peru	Valencia, Fernando	LIMA	Peru	publication	Aggressive Lymphomas
370	Treatment of high risk aggressive B cell lymphomas with DA EPOCH R- a retrospective analysis	Panny, Michael	Vienna	Austria	publication	Aggressive Lymphomas
371	R- DAEPOCH as a first line treatment for high grade B cell lymphoma and diffuse large B cell lymphomawith unfavorable features	Romejko-Jarosinska, Joanna	Warsaw	Poland	publication	Aggressive Lymphomas
372	R-DA-EPOCH improves the outcome over that of the R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high IPI, but not for double expressor lymphoma	Xu, Wei	Nanjing	China	publication	Aggressive Lymphomas
373	Newly Diagnosed Diffuse Large B Cell Lymphoma Benefit from the Addition of Thymosin Alpha 1 to R-CHOP: A Propensity Matched Study from Single institution	Huang, Hui-qiang	Guangzhou	China	publication	Aggressive Lymphomas
374	Outcome of Diffuse Large B-cell Lymphoma in Patients over the age of 70 years: Real World Experience in a large U.K. District General Hospital	Addada, Juanah	Derby	UK	publication	Aggressive Lymphomas
375	The role of maintenance therapy in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis	Rozental, Alon	Petah-Tikva	Israel	publication	Aggressive Lymphomas
376	Double hit lymphoma in the Northern region of England - a retrospective analysis of patient and disease characteristics, treatment delivered and survival	Creasey, Thomas	Newcastle-upon-Tyne	UK	publication	Aggressive Lymphomas
377	Negative impact of zoledronic acid in R-CHOP treated DLBCL with bone metastasis.	Inoue, Norihito	Tokyo	Japan	publication	Aggressive Lymphomas
378	Diffuse large B cell Non-Hodgkins Lymphoma: R-mini CHOP or physician's choice dose adjusted chemotherapy in patients over 80 years old	Paschalis, Alec	Portsmouth	UK	publication	Aggressive Lymphomas
379	Treatment and survival of primary effusion lymphoma (PEL): a population-based study among 25 patients diagnosed in the Netherlands between 2002 and 2015	Lugtenburg, Pieterella	Rotterdam	Netherlands	publication	Aggressive Lymphomas
380	Burkitt lymphoma - Multicenter Retrospective Data Analysis from the Czech Lymphoma Study Group - NiHiL project	Sýkorová, Alice	Hradec Kralove	Czech Republic	publication	Aggressive Lymphomas
381	Preliminary Analysis of Lenalidomide Maintenance after Methotrexate-Temozolomide-Rituximab Induction in Older Patients with PCNSL	Rubenstein, James	San Francisco	USA	publication	Aggressive Lymphomas
382	Effective Treatments are Required for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) with Primary Refractory Disease	Salas , Queralt	Barcelona	Spain	publication	Aggressive Lymphomas
383	Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from the Spanish Group GELTAMO	Martín, Alejandro	Salamanca	Spain	publication	Aggressive Lymphomas
384	Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B- and T-cell Lymphoma	Tisi, Maria	Vicenza	Italy	publication	Aggressive Lymphomas
385	Patients' decision-making, experiences and preferences regarding Pixantrone treatment in relapsed aggressive B-cell lymphoma: research protocol for a longitudinal qualitative study	van Hoogdalem, Lothar	Rotterdam	Netherlands	publication	Aggressive Lymphomas
386	RESULTS OF A PROSPECTIVE PHASE II TRIAL WITH OFATUMUMAB AS PART OF REDUCED INTENSITY CONDITIONING REGIMEN IN HIGH RISK NON-HODGKIN B LYMPHOMA PATIENTS: A GELTAMO TRIAL.	Cabrero, Monica	Salamanca	Spain	publication	Aggressive Lymphomas
387	Impact of post-transplant lymphoproliferative disorder subtype on survival	Koff, Jean	Atlanta, GA	USA	publication	Aggressive Lymphomas
388	PTLD: Survival and analysis of prognostic factors in a cohort of 138 patients from a single institution.	Bajwa, Ravneet	gainesville	USA	publication	Aggressive Lymphomas
389	Allograft rejection associated with immunosuppression reduction for post-transplant lymphoproliferative disorder: A 20-year single-institutional experience.	Franke, Aaron	Gainesville	USA	publication	Aggressive Lymphomas
390	Post-transplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series	Bobillo, Sabela	Barcelona	Spain	publication	Aggressive Lymphomas
391	Presentations, treatment complications and outcomes in HCV-infected B-cell lymphoma patients treated with immunochemotherapy: a single institute retrospective study	Pei, Sung-Nan	Kaohsiung City	Taiwan (Republic of China)	publication	Aggressive Lymphomas
392	Treatment patterns and outcomes in the DLBCL cohort of a study (MONITOR-GCSF) assessing biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropenia	Gascon, Pere	Barcelona	Spain	publication	Aggressive Lymphomas
393	Outcomes in Pediatric Patients with Post-transplant lymphoproliferative disorder (PTLD): Analysis of a 20-year single-institutional experience.	Franke, Aaron	Gainesville	USA	publication	Aggressive Lymphomas
394	Treatment of newly diagnosed Central Nervous System (CNS) lymphoma patients based on co-morbidities & performance status: a single-centre experience.	Lim, Yeong Jer	Liverpool	UK	publication	Aggressive Lymphomas
395	Characteristics and natural history of primary vitreoretinal lymphoma (PVL) compared to the primary lymphoma of the CNS (PCNSL)	Pytlík, Robert	Praha 2	Czech Republic	publication	Aggressive Lymphomas
396	CNS RELAPSE IN PATIENTS WITH DLBCL ACCORDING TO CNS-IPI SCORE AND THE INITIAL THERAPY	VERROU, EVGENIA	THESSALONIKI	Greece	publication	Aggressive Lymphomas
397	Initial management of Primary Central Nervous System Lymphoma in Spain in the last decade. The experience of the GELTAMO and Spanish Neuro-Oncology groups.	Mercadal, Santiago	Barcelona	Spain	publication	Aggressive Lymphomas
398	Craniotomy versus biopsy for primary CNS lymphoma: An institutional series and nationwide NCDB-PUF and SEER database study.	Iwamoto, Fabio	New York	USA	publication	Aggressive Lymphomas

399	FERTILITY AND SOCIAL REINTEGRATION AFTER MODIFIED CODOX-M/IVAC WITH OR WITHOUT RITUXIMAB: A QUESTIONNAIRE SURVEY OF NON-HODGKIN LYMPHOMA	Toyoda, Kosuke	Tokyo	Japan	publication	Aggressive Lymphomas
400	Preliminary results for a multimodality imaging approach for early detection and prediction of cardiotoxicity in doxorubicin-treated patients with malignant lymphoma	Laursen, Adam	Copenhagen	Denmark	publication	Aggressive Lymphomas
401	Prognostic value of Ki-67, MIPI score and SUV max of the PET SCAN: Result of a Single Center Experience with Mantle-Cell Lymphomas	Nguyen, Thuy	Brussels	Belgium	publication	Mantle Cell Lymphoma
402	Autologous stem cell transplantation is infrequently utilized but associated with improved overall survival in elderly patients with mantle cell lymphoma	Cohen, Jonathon	Atlanta	USA	publication	Mantle Cell Lymphoma
403	Short course of R-HyperCVAD/MTX/Ara-C followed by ASCT as first-line Therapy in Mantle Cell Lymphoma patients prolongs progression free survival to more than 9 years.	Andrade Campos, Marcio	Barcelona	Spain	publication	Mantle Cell Lymphoma
404	Improved Outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/- rituximab for reasons other than progression of Disease	Chen, Wendy	Houston	USA	publication	Mantle Cell Lymphoma
405	PROGRESSION-FREE SURVIVAL SHORTENS AFTER EACH RELAPSE IN PATIENTS WITH FOLLICULAR LYMPHOMA TREATED IN THE RITUXIMAB ERA	Rivas-Delgado, Alfredo	Barcelona	Spain	publication	Indolent Lymphoma
406	Radioimmunotherapy for follicular lymphoma achieves excellent lymphoma control in first line and relapse: 8 year follow up data of 281 patients from the international RIT-registry	Hohloch, Karin	Chur	Switzerland	publication	Indolent Lymphoma
407	BEYOND RITUXIMAB MAINTENANCE. RELAPSING FOLLICULAR LYMPHOMA DURING OR AFTER END OF RITUXIMAB MAINTENANCE. ANALYSIS OF CZECH LYMPHOMA STUDY GROUP (CLSG) DATABASE.	Janikova, Andrea	Brno	Czech Republic	publication	Indolent Lymphoma
408	Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma	Cencini, Emanuele	Siena	Italy	publication	Indolent Lymphoma
409	Retrospective analysis on R-DHAP/Ox and ASCT as salvage treatment for relapsed/refractory high risk follicular lymphoma.	Ghione, Paola	Torino	Italy	publication	Indolent Lymphoma
410	Prolonged molecular and clinical remissions in follicular lymphoma patients treated with HDT/ASCT and combination immunotherapy with rituximab and interferon α .	Berinstein, Neil	Toronto	Canada	publication	Indolent Lymphoma
411	An international comparison of the efficacy, cost and myelotoxicity of first-line therapy for advanced follicular non-Hodgkin lymphoma	Kesavan, Murali	Perth	Australia	publication	Indolent Lymphoma
412	Clinical characteristics and prognosis of elderly (>70 years) follicular lymphoma in the rituximab era: multicentre retrospective analysis of the GELTAMO Spanish group	Alcoceba, Miguel	-	Spain	publication	Indolent Lymphoma
413	ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA	Shichijo, Takafumi	Tokyo	Japan	publication	Indolent Lymphoma
414	Risk of secondary hematological malignancy in patients with follicular lymphoma	Prusila, Roosa	Oulu	Finland	publication	Indolent Lymphoma
415	The prognostic value of FLIPI in the era of rituximab	Juznic Setina, Tanja	Ljubljana	Slovenia	publication	Indolent Lymphoma
416	Pretreatment soluble interleukin-2 receptor level was a robust prognostic factor in follicular lymphoma in rituximab era	Kusano, Yoshiharu	Tokyo	Japan	publication	Indolent Lymphoma
417	LONG-TERM FOLLOW-UP AND PREDICTORS OF POOR OUTCOME IN PATIENTS WITH FOLLICULAR LYMPHOMA UNDERGOING FRONT-LINE TREATMENT WITH CHEMOIMMUNOTHERAPY: A SINGLE CENTER EXPERIENCE.	Donato, Eva M ^a	Valencia	Spain	publication	Indolent Lymphoma
418	Gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-Hodgkin lymphomas receiving bendamustine and rituximab	Cencini, Emanuele	Siena	Italy	publication	Indolent Lymphoma
419	Prognostic value of lymphocyte/monocyte ratio and neutrophil/lymphocyte ratio at diagnosis of follicular lymphoma.	Lee, Shing Fung	Hong Kong	Hong Kong	publication	Indolent Lymphoma
420	The value of prognostic nutritional index at diagnosis in patients with follicular lymphoma: a retrospective cohort study	Lee, Shing Fung	Hong Kong	Hong Kong	publication	Indolent Lymphoma
421	A retrospective study of the diagnosis and the treatment-associated mortality of patients with primary ocular adnexal mucosa-associated lymphoid tissue (POA-MALT) lymphoma in Japan.	Masuda, Yuya	Tohon-shi	Japan	publication	Indolent Lymphoma
422	Clinical features and survival outcomes on lymphoplasmacytic lymphoma patients with non-IgM paraproteinemia compared with IgM paraproteinemia in Korea	Kang, Jihoon	Seoul	Korea, Republic of	publication	Indolent Lymphoma
423	PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA - THE ROLE OF MEDIASTINAL RADIATION	Afonso, Sofia	Porto	Portugal	publication	Extranodal Lymphoma
424	Primary extranodal non-Hodgkin's lymphoma of the liver (PLL).	Lepkov, Sergey	MOCKBA	Russian Federation	publication	Extranodal Lymphoma
425	Outcome of primary diffuse large B-cell lymphoma of the stomach – A single institute experience	Mehmood, Tahir	Lahore	Pakistan	publication	Extranodal Lymphoma
426	Long-term follow-up of patients with non-Hodgkin Primary Diffuse Large B-Cell Lymphoma of the Stomach: Better outcome after immunochemotherapy	Hatjiharissi, Evdoxia	Thessaloniki	Greece	publication	Extranodal Lymphoma
427	Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Study of 303 Cases from China Lymphoma Patient Registry	Song, Yuqin	Beijing	China	publication	Extranodal Lymphoma
428	Clinical Features and Prognoses of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Analysis of 139 Chinese Cases with Immunophenotyping from CLAP	Song, Yuqin	Beijing	China	publication	Extranodal Lymphoma
429	CNS targeting chemotherapy is associated with superior survival in patients with testicular lymphoma – results from Finnish-Danish retrospective study	Mannisto, Susanna	Helsinki	Finland	publication	Extranodal Lymphoma
430	3D conformal radiotherapy (3D-CRT) at primary orbital lymphoma (OL) with different fractionation	Chumachenko, Anastasia	Saint-Petersburg	Russian Federation	publication	Extranodal Lymphoma

431	Absolute peripheral monocyte count predicts progression-free survival in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	Xu, Wei	Nanjing	China	publication	Extranodal Lymphoma
432	Treatment results according to cellular subtypes of gastric MALT lymphoma	Mallaev, Makhsud	Tashkent	Uzbekistan	publication	Extranodal Lymphoma
433	INCIDENCE AND OUTCOME OF PRIMARY EXTRANODAL FOLLICULAR LYMPHOMAS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) REGISTRY.	Janikova, Andrea	Brno	Czech Republic	publication	Extranodal Lymphoma
434	MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated <i>IGHV</i> gene	Qin, Shuchao	Nanjing	China	publication	CLL
435	Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables	Qin, Shuchao	Nanjing	China	publication	CLL
436	Portuguese real-life experience with ibrutinib outside clinical trials – a multicenter analysis	Silva, Sofia	Lisbon	Portugal	publication	CLL
437	Effects on the human immune system after Obinutuzumab monotherapy treatment.	Garcia-Munoz, Ricardo	Logroño	Spain	publication	CLL
438	Comparison of innate immunity changes following Ibrutinib and Venetoclax treatment of relapsed Chronic Lymphocytic Leukaemia.	Mason, Kylie	Parkville	Australia	publication	CLL
439	CHRONIC LYMPHOCYTIC LEUKEMIA INVOLVEMENT OF CENTRAL NERVOUS SYSTEM: A SINGLE CENTRE EXPERIENCE	Smiljanic, Mihailo	Belgrade	Serbia	publication	CLL
440	Minimal residual disease assessment in multiple myeloma: Utility & feasibility in resource constraint settings of India.	Sachdeva, Man Updesh	Chandigarh	India	publication	Plasma Cell Disorders
441	HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP	Hus, Iwona	Lublin	Poland	publication	Plasma Cell Disorders
442	Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Efficacy and Safety Update (CASTOR)	Lentzsch, Suzanne	New York, NY	USA	publication	Plasma Cell Disorders
443	Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Efficacy and Safety Update (POLLUX)	Bahlis, Nizar	Calgary, Alberta	Canada	publication	Plasma Cell Disorders
444	Epidemiological and humanistic burden of Cutaneous T-cell Lymphomas: results of a systematic review	Dalal, Mehul	Cambridge	USA	publication	NK and T-cell Lymphomas
445	ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population	Li, Wenyu	Guangzhou	China	publication	NK and T-cell Lymphomas
446	Circulating low absolute CD4 ⁺ T cell counts may predict poor prognosis in patients with extranodal NK/T-cell lymphoma, nasal type	Xu, Wei	Nanjing	China	publication	NK and T-cell Lymphomas
447	DUSP22 and <i>TP63</i> rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study	Pedersen, Martin	Aarhus	Denmark	publication	NK and T-cell Lymphomas
448	Serum 2-hydroxyglutarate, a predictive biomarker of the presence of <i>IDH2</i> mutations in AITL patients	Brouin, Sophie	Villejuif	France	publication	NK and T-cell Lymphomas
449	The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With peripheral T-cell lymphoma	Gurion, Ronit	Petach Tikva	Israel	publication	NK and T-cell Lymphomas
450	Efficacy and safety of pegaspargase, gemcitabine, dexamethasone, and cisplatin combined chemotherapy in newly diagnosed extranodal NK/T cell lymphoma	Zhang, Liling	Wuhan	China	publication	NK and T-cell Lymphomas
451	A phase II trial of Bendamustine, carboplatin and dexamethasone (BCD) for refractory or relapsed peripheral T-cell lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial	Park, Byeong-Bae	Seoul	Korea, Republic of	publication	NK and T-cell Lymphomas
452	Pegylated liposomal doxorubicin combined with cyclophosphamide, vincristine/vindesine, and prednisone in patients with aggressive T-cell lymphoma: preliminary results of a phase II study	Xia, Zuguang	Shanghai	China	publication	NK and T-cell Lymphomas
453	The effect of long term maintenance chemotherapy for aggressive adult T cell leukemia/lymphoma	Tsukaguchi, Machiko	Sakai City	Japan	publication	NK and T-cell Lymphomas
454	Richter transformation of T-cell large granular cell leukemia	Nakmaura, Naoya	Isehara	Japan	publication	NK and T-cell Lymphomas
455	Clinico-pathological profile and CMYC immunoreactivity of ALK positive Large B cell lymphoma: Report of Nine cases.	Mallick, Saumyaranjan	New Delhi	India	publication	NK and T-cell Lymphomas
456	Gemcitabine plus liposomal doxorubicin for relapsed refractory T-cell lymphomas	Waller, Allyson	Columbus	USA	publication	NK and T-cell Lymphomas
457	The efficacy and tolerance of chidamide, prednisone, cyclophosphamide and thalidomide (C-PCT) in relapsed or refractory peripheral T-cell lymphoma: a pilot study	Xu, Wei	Nanjing	China	publication	NK and T-cell Lymphomas
458	Established cell lines and patient-derived xenografts represent equally relevant models of aggressive lymphomas	Klener, Pavel	Prague	Czech Republic	publication	Drugs preclinical
459	Constitutive Expression of γ H2AX Predicts Better Response to Histone Deacetylase Inhibitor in Diffuse Large B-cell Lymphoma	Liu, Yan-Yan	Zhengzhou	China	publication	Drugs preclinical
460	Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Hodgkin Lymphoma	Szydowski, Maciej	Warsaw	Poland	publication	Drugs preclinical
461	Targeting Heat Shock Protein 90 and Its Downstream Signaling Hubs for the Treatment of Mantle Cell Lymphoma	Liu, Hanqing	Zhenjiang	China	publication	Drugs preclinical
462	L-type Cav 1.2 Calcium Channel Participates in Rituximab-induced Apoptosis in Diffuse Large B-cell Lymphoma	Zhang, Pei-Pei	Zhengzhou	China	publication	Drugs preclinical
463	MALT1 inhibition using the Small Molecule Inhibitor Mi-2 Efficiently Induces Apoptosis in CLL Cells	Herishanu, Yair	Tel-Aviv	Israel	publication	Drugs preclinical
464	Bortezomib prevents development of cytarabine resistance in a mantle cell lymphoma <i>in vitro</i> model	Freiburghaus, Catja	Lund	Sweden	publication	Drugs preclinical
465	GSK-3 β inhibitor, 9-ING-41 reduces cell viability and halts proliferation of B-cell Lymphoma	Karmali, Reem	Chicago	USA	publication	Drugs preclinical
466	Metabolic changes associated with metformin potentiates anti-Bcl-2 inhibitor, ABT-199, and CDK9 inhibitor, BAY-1143572 and reduces viability of lymphoma cells	Karmali, Reem	Chicago	USA	publication	Drugs preclinical
467	The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory activity towards tumor-infiltrating macrophages	Ding, Ning	Beijing	China	publication	Drugs preclinical
468	The effect of an immunomodulatory drug on the viability and surface molecule expression of chronic lymphocytic leukemia cells	Barna, Gábor	Budapest	Hungary	publication	Drugs preclinical

469	Molecular mechanisms and combination strategies with PI3K and BTK inhibitors to overcome intrinsic and acquired resistance in preclinical models of ABC-DLBCL	Paul, Juliane	Berlin	Germany	publication	Drugs preclinical
470	Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with HDACi in Models of PTCL	Scotto, Luigi	New York	USA	publication	Drugs preclinical
471	Targeting Bcl-2 in ALK+ ALCL: at the crossroads between autophagy and apoptotic cell death	Brousset, Pierre	Toulouse	France	publication	Drugs preclinical
472	A preliminary efficacy study of chidamide in combination with DICE regimen on relapsed or refractory B cell lymphomas	Song, Yu	Beijing	China	publication	Phase I-II
473	Absence of pharmacokinetic interaction of ofatumumab and bendamustine in patients with indolent B-cell Non-Hodgkin's Lymphoma (iNHL)	Forero-Torres, Andres	Birmingham	USA	publication	Phase I-II
474	ME-401, a Novel, Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase p110δ (PI3Kδ) in Early Clinical Development for B-cell Lymphoid Malignancies	Ghalie, Richard	San Diego	USA	publication	Phase I-II
475	ONO-4059 (GS-4059), a next generation BTK inhibitor, monotherapy in Patients with B-cell malignancies in the Japanese Phase 1, Dose-Escalation Study	Ando, Kiyoshi	Isehara	Japan	publication	Phase I-II
476	Pharmacokinetic analysis and clinical results of the phase 1 dose escalation and expansion CXD101 trial in relapsed, refractory lymphoma	Eyre, Toby	Oxford	UK	publication	Phase I-II
477	Safety run-in of copanlisib in combination with rituximab plus bendamustine in patients with relapsed indolent non-Hodgkin's lymphoma	Gerecitano, John	New York	USA	publication	Phase I-II
478	Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary results of the BIBLOS phase Ib LYSA Study.	BONNET, Christophe	Angleur	Belgium	publication	Phase I-II
479	Engaging Administrative Data to Determine Time to Diagnosis and Treatment of Lymphoma: A Population Based Study	Skrabek, Pamela	Winnipeg	Canada	publication	Phase I-II
480	PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II-IV PERIPHERAL T-CELL NON-HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T-CELL CONSORTIUM	Lunning, Matthew	Omaha	USA	publication	Phase I-II
481	Dual PI3K δ/γ Inhibitor RP6530 in Patients with Relapsed/Refractory T-cell Lymphoma: Dose Escalation Findings.	Oki, Yasuhiro	Houston	USA	publication	Phase I-II
482	PICC-related thrombosis in patients with aggressive lymphoma treated with DA-EPOCH – how to prevent it?	Mitrovic, Zdravko	Zagreb	Croatia	publication	Miscellaneous
483	High Rate of Morbid Central Line Associated Complications During Treatment with Dose-Adjusted R-EPOCH Therapy for Non-Hodgkin Lymphoma.	Reagan, Patrick	Rochester	USA	publication	Miscellaneous
484	Subcutaneous Rituximab in B-cell non-Hodgkin Lymphoma: a single-center experience	Sanchez-Gonzalez, Blanca	Barcelona	Spain	publication	Miscellaneous
485	PHARMOVIGILANCE OF RITUXIMAB BIOSIMILAR IN THE TREATMENT OF LYMPHOMAS IN ARGENTINA	Milone, Gustavo	Buenos Aires	Argentina	publication	Miscellaneous
486	Real-life use of bendamustine for B-cell non-Hodgkin lymphoma in a community hospital in Japan – retreatment with bendamustine is safe and feasible –	Matsuki, Eri	Tokyo	Japan	publication	Miscellaneous
487	Thalidomide in relapsed lymphoma: 5 years of experience from Southend University Hospital NHS Foundation Trust	Blacker, Edward	Southend	UK	publication	Miscellaneous
488	Comparative analysis of predictive models for thromboembolic events in lymphoma patients	Antic, Darko	Belgrade	Serbia	publication	Miscellaneous
489	Incidence and Survival of Non-Hodgkin Lymphoma at Oncosalud -AUNA: A Dynamic Cohort Study	Flores, Claudio J.	Lima	Peru	publication	Miscellaneous
490	Langerhans cell histiocytosis in adults is associated with increased hematologic and solid malignancies	Ma, Jennifer	New York	USA	publication	Miscellaneous
491	A prospective study to evaluate the utility of geriatric assessment and intervention in patients with lymphoproliferative disorders in a tertiary hospital	Bastos-Oreiro, Mariana	Madrid	Spain	publication	Miscellaneous
OT07	Phase I/II study of Brentuximab Vedotin in refractory/relapsed Hodgkin lymphoma patients treated by chemotherapy (ICE) in second line before autologous transplantation.	Stamatoullas, Aspasia	Rouen	France	publication	Ongoing trials
OT08	A Phase 1/2 study of pixantrone, etoposide, bendamustine and, in CD20+ tumors, rituximab in patients with relapsed aggressive B- or T-cell lymphomas – The P[R]EBEN study	D'Amore, Francesco	Aarhus C	Denmark	publication	Ongoing trials
OT09	DEVEC: A PHASE II STUDY OF METRONOMIC CHEMOTHERAPY IN ELDERLY NON-FIT PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMAS (promoted by FIL)	COX, M CHRISTINA	ROMA	Italy	publication	Ongoing trials
OT10	PET/CT-GUIDED BIOPSY FOR THE DIAGNOSIS OF LYMPHOMA	Broccoli, Alessandro	Bologna	Italy	publication	Ongoing trials
OT11	FIL-PTCL13: Phase Ib/II Study of Romidepsin/CHOEP Followed by High-Dose Chemotherapy and Transplantation in Untreated Peripheral T-cell Lymphomas.	Chiappella, Annalisa	Torino	Italy	publication	Ongoing trials
OT12	A MRD-guided approach for the combination of ibrutinib to venetoclax in relapsed/refractory patients with chronic lymphocytic leukemia (IMPROVE study)	Ghia, Paolo	Milano	Italy	publication	Ongoing trials
OT13	Phase 3 Study of Ibrutinib in Combination With Rituximab Versus Placebo in Combination With Rituximab in Patients With Treatment-Naïve Follicular Lymphoma (PERSPECTIVE)	Rule, Simon	Plymouth	UK	publication	Ongoing trials
OT14	An ongoing phase 2 study of ibrutinib combined with venetoclax in patients with treatment-naïve CLL/SLL	Ghia, Paolo	Milan	Italy	publication	Ongoing trials